





Section: 8. Immunomodulators and antineoplastics > 8.2. Antineoplastics and supportive medicines > 8.2.4. Hormones and antihormones

		EMLc	ATC codes: H02AB02		
Indication	Lymphoid leukaemia, not elsewhere classified	ICD11 code: 2C03.3			
INN	Dexamethasone				
Medicine type	Chemical agent				
List type	Complementary (EML) (EMLc)				
Formulations	Oral > Liquid: 2 mg per 5 mL (EMLc) Oral > Solid: 2 mg (EMLc) ; 4 mg Parenteral > General injections > unspecified: 4 mg per mL in 1 mL ampoule (as disodium phosphosphate salt)				
EML status history	First added in 1977 (TRS 615) Changed in 2015 (TRS 994)				
Sex	All				
Age	Also recommended for children				
Therapeutic alternatives	The recommendation is for this specific medicine				
Patent information	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> . 				
Tags	Cancer				
Wikipedia	<a href="#">Dexamethasone</a> 				
DrugBank	<a href="#">Dexamethasone</a> 				

### Summary of evidence and Expert Committee recommendations

In 2015, as part of the comprehensive review of cancer medicines undertaken by the Expert Committee, listing for asparaginase on the complementary list of the EML and EMLc for use in treatment protocols for acute lymphoblastic leukaemia (ALL) was recommended. The relevant extract from TRS994 regarding the Expert Committee's 2015 consideration of treatment protocols for ALL is attached.

[Expert Committee report](#)

